The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Aralez Pharmaceuticals Inc

TSX: ARZ
Delayed quote

$6.37

Today's change-0.29 -4.35%
Updated August 25 2:48 PM EDT. Delayed by at least 15 minutes.
 

Aralez Pharmaceuticals Inc

TSX: ARZ
Delayed quote

$6.37

Today's change-0.29 -4.35%
Updated August 25 2:48 PM EDT. Delayed by at least 15 minutes.

Sharp drop following new 100-day high

Aralez Pharmaceuticals Inc is sharply lower today, dropping $0.29 or 4.35% to $6.37 after setting a new 100-day high. Shares have lost 3.78% over the last five days, but have gained 378.95% over the last year to date. This security has outperformed the S&P TSX by 334.38% during the last year.

Key company metrics

  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS-$2.03
Updated August 25 2:48 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-224.36%

Aralez Pharmaceuticals Inc has a net profit margin of -224.36%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.13%Sector:Industry:

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue13866
Total other revenue--------
Total revenue13866
Gross profit96----
Total cost of revenue33----
Total operating expense30462014
Selling / general / administrative23371712
Research & development1432
Depreciation / amortization21----
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-17-38-14-8
Interest income (expense), net non-operating-10----
Gain (loss) on sale of assets--------
Other--------
Income before tax-18-33-14-8
Income after tax-17-34-13-8
Income tax, total-11-10
Net income-17-34-13-8
Total adjustments to net income--------
Net income before extra. items-17-34-13-8
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-17-34-13-8
Inc. avail. to common incl. extra. items-17-34-13-8
Diluted net income-17-34-13-8
Dilution adjustment--------
Diluted weighted average shares64523333
Diluted EPS excluding extraordinary itemsvalue per share-0.27-0.65-0.40-0.25
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.27-0.65-0.40-0.25